Literature DB >> 21983080

B cells that produce immunoglobulin E mediate colitis in BALB/c mice.

Jennifer C Hoving1, Frank Kirstein, Natalie E Nieuwenhuizen, Lizette C E Fick, Elias Hobeika, Michael Reth, Frank Brombacher.   

Abstract

BACKGROUND & AIMS: Induction of colitis in mice by administration of oxazolone is mediated by T-helper (Th) 2 cells and has features of human ulcerative colitis. We investigated whether activation of interleukin (IL)-4Rα on T and B cells determines their effector functions and mediates oxazolone-induced colitis.
METHODS: We studied induction of colitis with oxazolone in wild-type mice and those with CD4(+) T cells that did not express IL-4Rα (Lck(cre)IL-4Rα(-/lox)). We also generated mice with B cells that did not express IL-4Rα (mb1(cre)IL-4Rα(-/lox)) and studied induction of colitis.
RESULTS: Lck(cre)IL-4Rα(-/lox) mice did not develop colitis in response to oxazolone, and their levels of IL-4, IL-13, and immunoglobulin (Ig) E were reduced. Adoptive transfer of naïve, wild-type CD4(+) Th cells depleted of natural killer T cells to Lck(cre)IL-4Rα(-/lox) mice restored their susceptibility to colitis. In contrast, Lck(cre)IL-4Rα(-/lox) mice maintained their protection against colitis when IL-13-deficient CD4(+) T cells were transferred. These findings indicate that development of colitis involves not only natural killer T-cell functions, but also requires IL-13 production by CD4(+) T helper cells. Mb1(cre)IL-4Rα(-/lox) mice, which cannot produce IgE, were also protected against oxazolone-induced colitis. Blocking IgE binding significantly reduced mast cell numbers in colons and protected wild-type BALB/c mice from the onset of colitis.
CONCLUSIONS: IL-4 appears to induce CD4(+) Th2 cells to produce IL-13 and B cells to produce IgE, which together mediate oxazolone-induced colitis in mice.
Copyright © 2012 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21983080     DOI: 10.1053/j.gastro.2011.09.044

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  28 in total

Review 1.  Role of type 2 immunity in intestinal inflammation.

Authors:  Giorgos Bamias; Fabio Cominelli
Journal:  Curr Opin Gastroenterol       Date:  2015-11       Impact factor: 3.287

Review 2.  Cytokine Networks and T-Cell Subsets in Inflammatory Bowel Diseases.

Authors:  Mei Lan Chen; Mark S Sundrud
Journal:  Inflamm Bowel Dis       Date:  2016-05       Impact factor: 5.325

3.  IL-4-producing B cells regulate T helper cell dichotomy in type 1- and type 2-controlled diseases.

Authors:  Ramona Hurdayal; Hlumani H Ndlovu; Mélanie Revaz-Breton; Suraj P Parihar; Justin Komguep Nono; Melissa Govender; Frank Brombacher
Journal:  Proc Natl Acad Sci U S A       Date:  2017-09-15       Impact factor: 11.205

4.  Exogenous murine antimicrobial peptide CRAMP significantly exacerbates Ovalbumin-induced airway inflammation but ameliorates oxazolone-induced intestinal colitis in BALB/c mice.

Authors:  Yang Li; Xiaojie Chu; Cunbao Liu; Weiwei Huang; Yufeng Yao; Ye Xia; Pengyan Sun; Qiong Long; Xuejun Feng; Kui Li; Xu Yang; Hongmei Bai; Wenjia Sun; Yanbing Ma
Journal:  Hum Vaccin Immunother       Date:  2017-11-29       Impact factor: 3.452

5.  Chemically induced mouse models of acute and chronic intestinal inflammation.

Authors:  Stefan Wirtz; Vanessa Popp; Markus Kindermann; Katharina Gerlach; Benno Weigmann; Stefan Fichtner-Feigl; Markus F Neurath
Journal:  Nat Protoc       Date:  2017-06-01       Impact factor: 13.491

6.  Interleukin-19 contributes as a protective factor in experimental Th2-mediated colitis.

Authors:  Yasuyuki Fujimoto; Yasu-Taka Azuma; Yukiko Matsuo; Mitsuru Kuwamura; Nobuyuki Kuramoto; Mariko Miki; Naoki Azuma; Midori Teramoto; Kazuhiro Nishiyama; Takeshi Izawa; Hidemitsu Nakajima; Tadayoshi Takeuchi
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-12-09       Impact factor: 3.000

7.  The activation of Wnt signaling by a STAT6-dependent macrophage phenotype promotes mucosal repair in murine IBD.

Authors:  J Cosín-Roger; D Ortiz-Masiá; S Calatayud; C Hernández; J V Esplugues; M D Barrachina
Journal:  Mucosal Immunol       Date:  2015-11-25       Impact factor: 7.313

8.  STAT6 deficiency ameliorates severity of oxazolone colitis by decreasing expression of claudin-2 and Th2-inducing cytokines.

Authors:  Michael J Rosen; Rupesh Chaturvedi; M Kay Washington; Lindsay A Kuhnhein; Preston D Moore; Scott S Coggeshall; Elizabeth M McDonough; Jörn-Hendrik Weitkamp; Amar B Singh; Lori A Coburn; Christopher S Williams; Fang Yan; Luc Van Kaer; R Stokes Peebles; Keith T Wilson
Journal:  J Immunol       Date:  2013-01-09       Impact factor: 5.422

9.  Therapeutic activity of an interleukin-4/interleukin-13 dual antagonist on oxazolone-induced colitis in mice.

Authors:  Marion T Kasaian; Karen M Page; Susan Fish; Agnes Brennan; Timothy A Cook; Karen Moreira; Melvin Zhang; Michael Jesson; Kimberly Marquette; Rita Agostinelli; Julie Lee; Cara M M Williams; Lioudmila Tchistiakova; Paresh Thakker
Journal:  Immunology       Date:  2014-11       Impact factor: 7.397

10.  Retinoic acid prevents mesenteric lymph node dendritic cells from inducing IL-13-producing inflammatory Th2 cells.

Authors:  A Yokota-Nakatsuma; H Takeuchi; Y Ohoka; C Kato; S-Y Song; T Hoshino; H Yagita; T Ohteki; M Iwata
Journal:  Mucosal Immunol       Date:  2013-11-13       Impact factor: 7.313

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.